Want to see JP:2395 full AI Analyst Report?
Top Page
Shin Nippon Biomedical Laboratories, Ltd.
(2395)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥1,550.00
▼(-4.44% Downside)
Action:Reiterated
Date:08/07/26
The score is anchored by moderate financial performance: solid profitability but softer growth/margins, higher leverage, and uneven free-cash-flow conversion. Technicals are constructive but tempered by overbought RSI and the stock sitting slightly below the 200-day average. Valuation is a clear positive, supported by a low P/E and ~3.9% dividend yield.
Positive Factors
Business model resilience
The company's fee-for-service preclinical CRO model ties revenue to structural R&D spending by pharma/biotech. That creates recurring, project-driven demand and long sales cycles that favor established providers, supporting durable revenue visibility and client stickiness over months to years.
Negative Factors
Rising leverage
Leverage rising to about one times equity reduces financial flexibility and raises interest and refinancing risk. If profitability softens or cash flow remains uneven, the higher debt burden constrains capital allocation, increases downside in downturns, and limits strategic optionality over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model resilience
The company's fee-for-service preclinical CRO model ties revenue to structural R&D spending by pharma/biotech. That creates recurring, project-driven demand and long sales cycles that favor established providers, supporting durable revenue visibility and client stickiness over months to years.
Read all positive factors
Shin Nippon Biomedical Laboratories, Ltd. (2395) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥61.82B
Dividend Yield3.37%
Average Volume (3M)231.41K
Price to Earnings (P/E)11.5
Beta (1Y)0.89
Revenue Growth1.72%
EPS Growth6.07%
CountryJP
Employees1,680
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)109.70
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,640.00Price Target Upside1.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)94.9
Revenue Forecast (FY)¥38.37B
Shin Nippon Biomedical Laboratories, Ltd. Business Overview & Revenue Model
Company Description
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide arr...
How the Company Makes Money
The company primarily makes money by providing outsourced research services to customers developing new drugs and related biomedical products. Its core revenue stream is fee-for-service contract work in preclinical (non-clinical) stages, where cus...
Shin Nippon Biomedical Laboratories, Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.52B | 32.41B | 26.45B | 25.09B | 17.75B |
| Gross Profit | 15.83B | 16.57B | 14.28B | 13.05B | 9.69B |
| EBITDA | 6.09B | 8.83B | 8.98B | 9.49B | 9.49B |
| Net Income | 4.57B | 4.92B | 5.53B | 6.06B | 7.13B |
Balance Sheet | |||||
| Total Assets | 105.06B | 92.42B | 76.30B | 58.31B | 39.38B |
| Cash, Cash Equivalents and Short-Term Investments | 18.54B | 12.03B | 10.61B | 10.53B | 7.00B |
| Total Debt | 41.26B | 34.61B | 26.33B | 18.93B | 9.28B |
| Total Liabilities | 61.57B | 52.33B | 42.14B | 31.95B | 19.66B |
| Stockholders Equity | 43.12B | 40.02B | 34.11B | 26.21B | 19.56B |
Cash Flow | |||||
| Free Cash Flow | 3.15B | -3.82B | -6.50B | -951.70M | 4.34B |
| Operating Cash Flow | 8.33B | 7.04B | 2.11B | 4.00B | 5.95B |
| Investing Cash Flow | -6.79B | -11.69B | -6.91B | -5.93B | -4.27B |
| Financing Cash Flow | 4.51B | 5.91B | 5.32B | 6.27B | -4.91B |
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis
Positive
1622.00
Price Trends
1228.12
Positive
1300.48
Positive
1461.30
Positive
Market Momentum
68.00
Negative
72.68
Negative
88.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2395, the sentiment is Positive. The current price of 1622 is above the 20-day moving average (MA) of 1349.15, above the 50-day MA of 1228.12, and above the 200-day MA of 1461.30, indicating a bullish trend. The MACD of 68.00 indicates Negative momentum. The RSI at 72.68 is Negative, neither overbought nor oversold. The STOCH value of 88.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2395.
Shin Nippon Biomedical Laboratories, Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥61.82B | 11.51 | ― | 2.79% | 1.72% | 6.07% | |
63 Neutral | ¥134.07B | 17.16 | 6.11% | 3.34% | 3.88% | 26.78% | |
57 Neutral | ¥75.40B | 21.21 | ― | 2.28% | 2.94% | 57.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥4.81B | -1.44 | ― | 5.44% | -21.55% | -497.97% |
* Healthcare Sector Average
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,485.00
-67.96
-4.38%
JP:4694
BML
3,585.00
205.22
6.07%
JP:2183
Linical Co., Ltd.
213.00
-122.63
-36.54%
JP:4549
Eiken Chemical Co., Ltd.
2,287.00
-62.51
-2.66%
Shin Nippon Biomedical Laboratories, Ltd. Corporate Events
SNBL Corrects Earnings Per Share Figure in Q1 FY2026 Disclosure
Aug 5, 2026
Shin Nippon Biomedical Laboratories has corrected an error in its consolidated financial results release for the three months ended June 30, 2026, specifically in the summary information on page one. The revision concerns the basic earnings per sh...
Shin Nippon Biomedical Laboratories Lifts First-Half Earnings Forecast on Strong CRO Performance
Aug 5, 2026
Shin Nippon Biomedical Laboratories has sharply raised its consolidated earnings forecast for the first half of the fiscal year ending March 31, 2027, citing stronger-than-expected results in its CRO business. Revenue is now projected at ¥17,...
SNBL Sets New Management Structure and Highlights FY3/27 Q1 CRO Strategy
Aug 5, 2026
Shin Nippon Biomedical Laboratories, Ltd. outlined its new management structure and future strategic direction alongside reporting an overview of first quarter results for the fiscal year ending March 31, 2027. The briefing highlighted consolidate...
SNBL Delivers Strong Q1 Earnings and Confirms Dividend Outlook
Aug 5, 2026
Shin Nippon Biomedical Laboratories reported strong results for the quarter ended June 30, 2026, with revenue rising 21.5% year on year to ¥7,868 million and profit attributable to owners of the parent surging to ¥1,064 million. The turn...
Shin Nippon Biomedical Laboratories Keeps Annual Dividend at ¥50 as CRO Business Hits Record Highs
May 29, 2026
Shin Nippon Biomedical Laboratories has approved a year-end dividend of ¥30 per share from retained earnings for shareholders of record on March 31, 2026, bringing total annual dividends for the fiscal year to ¥50 per share, unchanged fr...
SNBL backs U.S. launch build-out for migraine drug Atzumi after licensing talks stall
May 11, 2026
Shin Nippon Biomedical Laboratories has outlined a new commercialization strategy for Atzumi, an intranasal dihydroergotamine therapy developed by U.S. subsidiary Satsuma Pharmaceuticals for acute migraine in adults. After securing FDA approval an...
Shin Nippon Biomedical Laboratories Outlines FY2026 Results and Strategic Focus
May 11, 2026
Shin Nippon Biomedical Laboratories presented materials for its consolidated financial results briefing for the fiscal year ended March 31, 2026, outlining performance and outlook across its core businesses. The briefing covers the company’s...
SNBL Posts Flat Revenue, Lower Profits but Stronger Balance Sheet and Cash Ahead of FY2027 Growth Push
May 11, 2026
Shin Nippon Biomedical Laboratories reported fiscal 2026 revenue of ¥32.5 billion, up slightly year on year, while operating profit fell 11.1% to ¥2.65 billion and profit attributable to owners of the parent declined 7.3% to ¥4.57 b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.